ABIVAX Société Anonyme (0RA9.L)
EUR 7.35
(-0.34%)
EUR 7.35
(-0.34%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 3.91 Million EUR | -13.25% |
| 2022 | 4.51 Million EUR | 3891.6% |
| 2021 | -119 Thousand EUR | -128.85% |
| 2020 | -52 Thousand EUR | 40.23% |
| 2019 | -87 Thousand EUR | 99.4% |
| 2018 | -14.56 Million EUR | -43.94% |
| 2017 | -10.11 Million EUR | 30.21% |
| 2016 | -14.49 Million EUR | 0.21% |
| 2015 | -14.52 Million EUR | -6521.05% |
| 2014 | -219.36 Thousand EUR | -154.73% |
| 2013 | -86.11 Thousand EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 6.21 Million EUR | 0.0% |
| 2023 Q2 | 1.91 Million EUR | 0.0% |
| 2023 Q4 | 1.86 Million EUR | 0.0% |
| 2023 FY | 3.91 Million EUR | -13.25% |
| 2022 Q4 | 2.21 Million EUR | 0.0% |
| 2022 FY | 4.51 Million EUR | 3891.6% |
| 2022 Q2 | 2.18 Million EUR | 0.0% |
| 2021 FY | -119 Thousand EUR | -128.85% |
| 2021 Q4 | -124 Thousand EUR | 0.0% |
| 2021 Q2 | -32 Thousand EUR | 0.0% |
| 2020 Q4 | -19 Thousand EUR | 0.0% |
| 2020 Q2 | -33 Thousand EUR | 0.0% |
| 2020 FY | -52 Thousand EUR | 40.23% |
| 2019 Q2 | -5000.00 EUR | 0.0% |
| 2019 FY | -87 Thousand EUR | 99.4% |
| 2019 Q4 | -82 Thousand EUR | 0.0% |
| 2018 Q4 | -8.17 Million EUR | 0.0% |
| 2018 FY | -14.56 Million EUR | -43.94% |
| 2018 Q2 | -6.38 Million EUR | 0.0% |
| 2017 Q2 | -5.37 Million EUR | 0.0% |
| 2017 FY | -10.11 Million EUR | 30.21% |
| 2017 Q4 | -4.74 Million EUR | 0.0% |
| 2016 Q4 | -5.87 Million EUR | 0.0% |
| 2016 Q2 | -8.61 Million EUR | 0.0% |
| 2016 FY | -14.49 Million EUR | 0.21% |
| 2015 FY | -14.52 Million EUR | -6521.05% |
| 2015 Q4 | -8.02 Million EUR | 0.0% |
| 2015 Q2 | -6.49 Million EUR | 0.0% |
| 2014 Q4 | -2.63 Million EUR | -199900.0% |
| 2014 Q2 | -453 Thousand EUR | -199900.0% |
| 2014 Q1 | -226.50 EUR | 0.0% |
| 2014 FY | -219.36 Thousand EUR | -154.73% |
| 2014 Q3 | -1318.00 EUR | 99.71% |
| 2013 FY | -86.11 Thousand EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Boiron SA | 358.08 Million EUR | 98.907% |
| Laboratorios Farmaceuticos Rovi, S.A. | 483.34 Million EUR | 99.19% |
| Vetoquinol SA | 291.37 Million EUR | 98.657% |
| Valneva SE | 52.83 Million EUR | 92.592% |
| AB Science S.A. | 587 Thousand EUR | -566.78% |
| Nanobiotix S.A. | 42.35 Million EUR | 90.76% |
| PHAXIAM Therapeutics S.A. | 1.32 Million EUR | -195.173% |
| Vivoryon Therapeutics N.V. | -3.09 Million EUR | 226.462% |
| BioSenic S.A. | 543 Thousand EUR | -620.81% |
| Formycon AG | 23.3 Million EUR | 83.205% |